Market Place
Sourcing Support
Kelonia`s In Vivo BCMA CAR-T KLN-1010 Phase 1 Data at ASCO
31 May 2026 //
BUSINESSWIRE
Lilly To Present Oncology Portfolio At ASCO Meeting 2026
22 May 2026 //
PR NEWSWIRE
Eli to buy Boston`s Kelonia for up to $7 Billion in Cancer Push
21 Apr 2026 //
BIOSPACE
Kelonia Investor Venrock to Clear 45x Return on Lilly Sale
20 Apr 2026 //
ENDPOINTS
Kelonia Therapeutics Clears FDA (IND) For KLN-1010, CAR-T Therapy
07 Jan 2026 //
PHARMIWEB
Kelonia Therapeutics Unveils Phase 1 Data On KLN-1010 BCMA CAR-T
09 Dec 2025 //
PHARMIWEB
Kelonia Therapeutics Presents First-In-Human BCMA CAR-T Data
24 Nov 2025 //
BUSINESSWIRE
Kelonia Doses First Patient In Ph 1 inMMyCAR For Multiple Myeloma
19 Aug 2025 //
BUSINESSWIRE
Kelonia Therapeutics to Present iGPS® Data at ASGCT 2025 Meeting
09 May 2025 //
BUSINESSWIRE
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
02 May 2024 //
BUSINESSWIRE
Kelonia to Present Preclinical Data Highlighting Therapeutic Potential
02 Apr 2024 //
BUSINESSWIRE
Kelonia Therapeutics Appoints Kristen Hege & Matha to Board of Directors
28 Mar 2024 //
BUSINESSWIRE
Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia
16 Feb 2024 //
ENDPTS
Astellas bets more than $800M on Kelonia`s delivery tech
15 Feb 2024 //
FIERCE BIOTECH
Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data
02 May 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.